# US 2013/0252908 A1 · Pharmaceutical composition, methods for treating and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252908 A1
- Document ID: US20130252908A1
- Status: Published application
- Kind: A1
- Application number: 13/833,097
- Filed: 2013-03-15
- Published: 2013-09-26
- Earliest claimed: 2012-03-20
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Eric Williams MAYOUX; Rolf GREMPLER; Thomas KLEIN
- Web page: https://patentgrep.com/patent/US20130252908A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/351: not condensed with another ring
- A61K 31/365: Lactones
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- H02M 7/2176: {comprising a passive stage to generate a rectified sinusoidal voltage and a controlled switching element in series between such stage and the output}
- H02P 7/29: using pulse modulation
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- H02M 1/4291: {by using a Buck converter to switch the input current}
- Y02B 70/10: Technologies improving the efficiency by using switched-mode power supplies [SMPS], i.e. efficient power electronics conversion e.g. power factor correction or reduction of losses in power supplies or efficient standby modes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- H02M: APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF (transformers H01F; dynamo-electric converters H02K47/00; controlling transformers, reactors or choke coils, control or regulation of electric motors, generators or dynamo-electric converters H02P)
- H02P: CONTROL OR REGULATION OF ELECTRIC MOTORS, ELECTRIC GENERATORS OR DYNAMO-ELECTRIC CONVERTERS; CONTROLLING TRANSFORMERS, REACTORS OR CHOKE COILS
- Y02B: CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS

## Abstract

The invention relates to the treatment of metabolic disorders in an overweight or obese patient characterized in that empagliflozin and one or more antiobesity drugs are administered to the patient.

## Claims

### Claim 1

A method for slowing the progression of, delaying or treating of pre-diabetes in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 2

A method for preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, hyperinsulinemia and metabolic syndrome in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 3

A method for preventing, slowing the progression of, delaying or treating of an onset of type 2 diabetes mellitus in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 4

A method for treating of overweight or obesity in a patient diagnosed of having one or more conditions selected from the group consisting of pre-diabetes, type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, hyperinsulinemia and metabolic syndrome comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 5

A method for improving glycemic control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 6

A method for preventing, slowing, delaying or reversing progression from impaired glucose tolerance, impaired fasting blood glucose, insulin resistance or from metabolic syndrome to type 2 diabetes mellitus in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 7

A method for preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabetes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, dyslipidemia, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis, in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 8

A method for reducing body weight and/or body fat, or preventing an increase in body weight and/or body fat, or facilitating a reduction in body weight and/or body fat, in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 9

A method for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of ectopic fat, in particular liver fat, in a patient diagnosed of being overweight or obese comprising administering empagliflozin and one or more antiobesity drugs to the patient.

### Claim 10

A pharmaceutical composition comprising empagliflozin and one or more antiobesity drugs and one or more pharmaceutically acceptable excipients.

### Claim 11 (depends on 10)

A pharmaceutical composition according to the claim 10, wherein the one or more antiobesity drugs are selected from the group consisting of sibutramine, orlistat, cetilistat, a combination of phentermine and topiramate, a combination of naltrexone and bupropion, lorcaserin, liraglutide.

### Claim 12 (depends on 10)

A pharmaceutical dosage form comprising a pharmaceutical composition according to the claim 10.

### Claim 13 (depends on 11)

A pharmaceutical dosage form comprising a pharmaceutical composition according to the claim 11.
